CS419786A2 - Method of grippal vaccine production - Google Patents

Method of grippal vaccine production

Info

Publication number
CS419786A2
CS419786A2 CS864197A CS419786A CS419786A2 CS 419786 A2 CS419786 A2 CS 419786A2 CS 864197 A CS864197 A CS 864197A CS 419786 A CS419786 A CS 419786A CS 419786 A2 CS419786 A2 CS 419786A2
Authority
CS
Czechoslovakia
Prior art keywords
vaccine
complex
mdp derivative
particle
influenza
Prior art date
Application number
CS864197A
Other languages
English (en)
Other versions
CS269981B2 (en
Inventor
Kuniaki Nerome
Akira Oya
Kunio Ohkuma
Atsuo Inoue
Original Assignee
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Health filed Critical Nat Inst Health
Publication of CS419786A2 publication Critical patent/CS419786A2/cs
Publication of CS269981B2 publication Critical patent/CS269981B2/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CS864197A 1985-06-06 1986-06-06 Method of grippal vaccine production CS269981B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60123341A JPH0688911B2 (ja) 1985-06-06 1985-06-06 インフルエンザワクチン及びその製造方法

Publications (2)

Publication Number Publication Date
CS419786A2 true CS419786A2 (en) 1989-04-14
CS269981B2 CS269981B2 (en) 1990-05-14

Family

ID=14858166

Family Applications (1)

Application Number Title Priority Date Filing Date
CS864197A CS269981B2 (en) 1985-06-06 1986-06-06 Method of grippal vaccine production

Country Status (12)

Country Link
US (1) US4826687A (cs)
EP (1) EP0205098B1 (cs)
JP (1) JPH0688911B2 (cs)
KR (1) KR940001373B1 (cs)
CN (1) CN1020407C (cs)
AT (1) ATE76756T1 (cs)
AU (1) AU585353B2 (cs)
CA (1) CA1262091A (cs)
CS (1) CS269981B2 (cs)
DE (1) DE3685519T2 (cs)
ES (1) ES8707113A1 (cs)
SU (1) SU1651782A3 (cs)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5897873A (en) * 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
WO1990001948A1 (en) * 1988-08-25 1990-03-08 The Liposome Company, Inc. Influenza vaccine and novel adjuvants
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
WO1991011174A1 (en) * 1990-01-25 1991-08-08 The University Of Colorado Foundation, Inc. Method for preventing immune suppression in trauma patients
JP2777258B2 (ja) * 1990-03-13 1998-07-16 第一製薬株式会社 ムラミルジペプチド含有脂質膜構造体
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
NZ240369A (en) * 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
AU1566095A (en) * 1994-02-24 1995-09-11 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
AU709262B2 (en) * 1995-10-17 1999-08-26 Board Of Regents, The University Of Texas System Insoluble drug delivery
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
WO1999040906A2 (en) * 1998-02-11 1999-08-19 Research Triangle Pharmaceuticals Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ATE259220T1 (de) 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
US7097849B2 (en) 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
RU2233654C2 (ru) * 1998-11-20 2004-08-10 Ртп Фарма Инк. Диспергируемые стабилизированные фосфолипидом микрочастицы
IL148685A0 (en) * 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
ES2469642T3 (es) 2000-04-20 2014-06-18 Jagotec Ag Procedimiento mejorado para partículas de fármaco insoluble en agua
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
ES2372746T3 (es) * 2000-09-20 2012-01-26 Jagotec Ag Micropartículas de fibrato estabilizadas.
WO2002067901A1 (en) * 2001-02-22 2002-09-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
AU2002254901A1 (en) * 2001-02-23 2002-10-03 Smithkline Beecham Biologicals S.A. Influenza vaccine formulations for intradermal delivery
CA2445120A1 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals Sa Devices for the intradermal administration of influenza vaccines
EP1416986A4 (en) * 2001-06-29 2005-12-14 Becton Dickinson Co INTRADERMIC DISTRIBUTION OF VACCINES AND GENE THERAPEUTIC AGENTS VIA MICROCANNULE
EP2241330A1 (en) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
US20050281832A1 (en) * 2003-12-05 2005-12-22 Campbell Robert L Methods of enhancing immune response in the intradermal compartment and compounds useful thereof
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
EP2139908A4 (en) * 2007-03-12 2011-02-16 Antigen Express Inc REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY
EP3023107A1 (en) 2008-04-21 2016-05-25 Nanobio Corporation Nanoemulsion influenza vaccine
JP2014520805A (ja) 2011-07-06 2014-08-25 ナノバイオ コーポレーション ヒト呼吸器合胞体ウイルスワクチン
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009258A (en) * 1972-09-25 1977-02-22 The Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
CH589453A5 (cs) * 1974-01-14 1977-07-15 Sandoz Ag
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
DE3068743D1 (en) * 1980-01-16 1984-08-30 Weder Hans G Process and dialysis-installation for the preparation of bilayer-vesicles and their use
EP0047480B1 (en) * 1980-09-05 1986-02-05 Institut Armand Frappier Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4327182A (en) * 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
FR2551758B1 (fr) * 1983-08-16 1986-01-31 Anvar Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
IL69720A (en) * 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions

Also Published As

Publication number Publication date
SU1651782A3 (ru) 1991-05-23
ES555748A0 (es) 1987-07-01
CN1020407C (zh) 1993-05-05
EP0205098B1 (en) 1992-06-03
EP0205098A3 (en) 1989-03-22
EP0205098A2 (en) 1986-12-17
KR870000075A (ko) 1987-02-16
CS269981B2 (en) 1990-05-14
ATE76756T1 (de) 1992-06-15
AU5836586A (en) 1986-12-18
KR940001373B1 (ko) 1994-02-21
JPS61282321A (ja) 1986-12-12
CA1262091A (en) 1989-10-03
DE3685519D1 (de) 1992-07-09
AU585353B2 (en) 1989-06-15
CN86103717A (zh) 1987-02-11
DE3685519T2 (de) 1993-01-21
US4826687A (en) 1989-05-02
ES8707113A1 (es) 1987-07-01
JPH0688911B2 (ja) 1994-11-09

Similar Documents

Publication Publication Date Title
CS419786A2 (en) Method of grippal vaccine production
CA1279012C (en) Process for preparing immunogenic complexes and pharmaceutical composition containing these complexes
AU722647B2 (en) Protein-lipid vesicles and autogenous vaccine comprising the same
DK440386D0 (da) Laegemiddelholdigt chlorfluorcarbon-aerosoldrivmiddelpraeparat
EP0047480B1 (en) Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
ES8506451A1 (es) Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas
SE8201351L (sv) Sett att framstella liposomberedningar
Ribi et al. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins
DK55891D0 (da) Matrix med immunomodulerende virkning
AU1433788A (en) Natural pulmonary surfactant, method of preparation and pharmaceutical compositions
EP0335133A3 (en) Drug delivery using pulmonary surfactant fo facilitate absorption
Alving et al. Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation
DE69023648D1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
CA2352563A1 (en) Method to produce inactivated w/o emulsion adjuvanted vaccines
ATE87467T1 (de) Pharmazeutische zubereitung.
EP0306912A3 (en) Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
GR1001093B (el) Απορροφητικό υλικό, μέ?οδος επίτευξης απορροφητικού υλικού, απορροφητικό υπό?εμα, μέ?οδος επίτευξης απορροφητικού υπο?έματος, και απορροφητικό αντικείμενο μιας χρήσεως.
Ruttkowski et al. Qualitative and quantitative changes in the antibody producing cell response to lipopolysaccharide induced after incorporation of the antigen into bacterial membrane phospholipid vesicles.
Bergers et al. Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice
SE8400934L (sv) Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner
GB2001995A (en) An immunostimulant, a process for preparing it, and compositions containing it
van Dalen et al. Preparation and characterization of liposomes with incorporated Neisseria gonorrhoeae protein IB and amphiphilic adjuvants
WO1991008771A3 (fr) Procede de culture intensive, in vitro, de souches de babesia divergens, procede de preparation d'exoantigenes et vaccin contenant ces antigenes